68Ga-NODAGA-Exendin-4的PET人体剂量学:β细胞显像示踪剂
本研究纳入6例高胰岛素性低血糖患者,静脉注射100 MBq 68Ga-NODAGA-exendin-4后于30、60、120、240分钟行4次PET/CT,计算器官时间积分活度系数并用OLINDA/EXM 1.1估算成人及儿童辐射剂量。成人平均总有效剂量很低(100 MBq标准注射剂量下0.71±0.07 mSv),肾脏为最高吸收剂量器官(47.3±10.2 mGy/100 MBq),儿童估算剂量亦低。结论认为该新型示踪剂成人及儿童有效辐射剂量均很低,低于其他多肽类示踪剂如生长抑素类似物(2.1-2.6 mSv/100 MBq)。
要点
- 成人100 MBq注射剂量下平均总有效剂量为0.71±0.07 mSv。
- 肾脏为最高吸收剂量器官,达47.3±10.2 mGy/100 MBq。
- 儿童估算有效剂量低,新生儿20 MBq为2.32±0.32 mSv。
核心结论
- 68Ga-NODAGA-exendin-4在成人和儿童中的有效辐射剂量均很低,适合作为研究工具尤其需重复检查时使用。
研究设计与样本
- 纳入6例高胰岛素性低血糖患者,静脉注射100 MBq示踪剂后于30、60、120、240分钟行4次PET/CT。
- 测定胰腺、肾脏、十二指肠及全身其余部位的示踪剂活度,计算时间积分活度系数。
- 应用OLINDA/EXM软件1.1版,采用参考成人男性和女性模型计算辐射剂量并估算儿童剂量。
主要发现
- 成人平均总有效剂量为0.71±0.07 mSv(标准注射剂量100 MBq)。
- 最高吸收剂量器官为肾脏,47.3±10.2 mGy/100 MBq。
- 新生儿注射20 MBq时估算有效剂量为2.32±0.32 mSv。
- 1岁儿童20 MBq时有效剂量降至0.77±0.11 mSv,5岁儿童30 MBq时为0.59±0.05 mSv。
关键数值与推荐
- 成人100 MBq标准注射剂量下平均总有效剂量0.71±0.07 mSv。
- 肾脏吸收剂量47.3±10.2 mGy/100 MBq。
- 新生儿20 MBq有效剂量2.32±0.32 mSv,1岁儿童20 MBq为0.77±0.11 mSv,5岁儿童30 MBq为0.59±0.05 mSv。
- 该示踪剂剂量低于其他多肽类示踪剂如生长抑素类似物(2.1-2.6 mSv/100 MBq)。
临床怎么用
- 该示踪剂辐射剂量低,适用于良性疾病患者(包括幼儿)及健康人的β细胞显像研究。
- 低剂量特性有利于需要重复PET检查的研究场景。
局限性
- 样本量仅6例高胰岛素性低血糖患者,儿童剂量为基于成人模型的估算而非直接测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-NODAGA-exendin-4 is a promising tracer for β-cell imaging using PET/CT. Possible applications include preoperative visualization of insulinomas and discrimination between focal and diffuse forms of congenital hyperinsulinism. There is also a significant role for this tracer in extending our knowledge on the role of β-cell mass in the pathophysiology of type 1 and type 2 diabetes by enabling noninvasive quantification of tracer uptake as a measure for β-cell mass. Calculating radiation doses from this tracer is important to assess its safety for use in patients (including young children) with benign diseases and healthy individuals. Methods: Six patients with hyperinsulinemic hypoglycemia were included. After intravenous injection of 100 MBq of the tracer, 4 successive PET/CT scans were obtained at 30, 60, 120, and 240 min after injection. Tracer activity in the pancreas, kidneys, duodenum, and remainder of the body were determined, and time-integrated activity coefficients for the measured organs were calculated. OLINDA/EXM software, version 1.1, was applied to calculate radiation doses using the reference adult male and female models and to estimate radiation doses to children. Results: The mean total effective dose for adults was very low (0.71 ± 0.07 mSv for a standard injected dose of 100 MBq). The organ with the highest absorbed dose was the kidney (47.3 ± 10.2 mGy/100 MBq). The estimated effective dose was 2.32 ± 0.32 mSv for an injected dose of 20 MBq in newborns. This dose decreased to 0.77 ± 0.11 mSv/20 MBq for 1-y-old children and 0.59 ± 0.05 mSv for an injected dose of 30 MBq in 5-y-old children. Conclusion: Our human PET/CT-based dosimetric calculations show that the effective radiation doses from the novel tracer 68Ga-NODAGA-exendin-4 are very low for adults and children. The doses are lower than reported for other polypeptide tracers such as somatostatin analogs (2.1-2.6 mSv/100 MBq) and are beneficial for application as a research tool, especially when repeated examinations are needed.
引用
- Boss M, Buitinga M, Jansen TJP, et al. PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging. J Nucl Med. 2019. PMID: 31519801. doi:10.2967/jnumed.119.228627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。